Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Shares Slide 7.3 Percent on Wider Q4 Net Loss and Predictions of More Red in 06

NEW YORK, Feb. 23 (GenomeWeb News) - Cepheid shares were down 7.31 percent, or $.71, at $9 in afternoon trade after the company reported a wider fourth-quarter net loss and forecast deeper losses in 2006.


Cepheid yesterday reported a a net loss of $3.2 million, or $.08 per share during the third quarter, compared with a net loss of $3.0 million, or $.07 per share during the same quarter last year.


The company said fourth quarter revenues rose 16 percent to $23.6 million from $20.3 million year over year, driven by 15 percent growth in product sales.


The company attributed the increase primarily to a growth in product sales, including sales of reagents and disposables, which increased to $22.2 million from $19.4 million in the year-ago period.


R&D spending during the quarter rose to $5.2 million, compared to $4.4 million during the fourth quarter last year.


Cepheid expects a net loss in the range of $7 million to $9 million in 2006 on product sales in the range of $94 million to $98 million.


As of Sept. 30, 2005, Cepheid had $16.1 million in cash and cash equivalents and $21.2 million in marketable securities.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.